Recent Updates — IMNM

Immunome Inc. entered into Amendment No. 4 to its License Agreement with Bristol-Myers Squibb Company, removing all future milestone and royalty payment obligations for the drug varegacestat (formerly AL102). In exchange, Immunome paid $20 million in cash and issued 4,425,487 shares of common stock. The company must file a resale registration statement by November 16, 2026. Immunome Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.

Immunome reported a net loss of $73.1 million for the second quarter ended June 30, 2026, with cash and marketable securities totaling $520.0 million as of June 30, 2026. The company announced that the U.S. FDA accepted its New Drug Application for varegacestat to treat adults with desmoid tumors, assigning a PDUFA target action date of April 28, 2027. Detailed Phase 3 RINGSIDE trial data presented at ASCO showed an 84% reduction in disease progression or death risk versus placebo (hazard ratio = 0.16). Additionally, the first patient was dosed in June 2026 for the Phase 1 trial of IM-1617 and in July 2026 for the Phase 1 trial of IM-3050. Immunome is a clinical-stage biotechnology company focused on developing targeted cancer therapies.